肺腺癌患者EGFR和KRAS基因突变与预后的相关性研究  

The correlation between EGFR and KRAS gene mutation and prognosis in patients with lung adenocarcinoma

作　　者：董延琥[1] 栾文强[1] 李兴坤[1] 朱晓静[1] 董利[1] 

机构地区：[1]濮阳市人民医院肿瘤内科,河南濮阳457000

出　　处：《癌症进展》2017年第6期650-653,共4页Oncology Progress

摘　　要：目的探讨肺腺癌患者表皮生长因子受体(EGFR)和KRAS基因突变与预后的相关性。方法选取134例肺腺癌患者的肺腺癌组织标本,应用探针扩增阻滞突变系统在PCR仪上进行EGFR和KRAS基因突变检测,分析EGFR和KRAS基因突变与肺腺癌患者临床病理特征及预后的关系。结果 134例患者中,EGFR基因突变53例,突变率为39.55%,KRAS基因突变6例,突变率为4.48%。肺腺癌患者EGFR基因突变率与年龄、吸烟史有关(P﹤0.01)。EGFR基因突变型患者的KRAS基因突变率低于EGFR基因野生型患者(P﹤0.05)。EGFR基因突变型患者的无进展生存期(PFS)长于EGFR基因野生型患者(P﹤0.05),KRAS基因野生型患者的PFS长于KRAS基因突变型患者(P﹤0.05)。结论 EGFR基因突变的肺腺癌患者KRAS基因更倾向于野生型,EGFR基因突变型或KRAS基因野生型的肺腺癌患者PFS更长。Objective To investigate the correlation between epidermal growth factor receptor（EGFR） and KRAS gene mutation and the prognosis in patients with lung adenocarcinoma. Method The specimens collected from 134 patients with newly diagnosed lung adenocarcinoma were analyzed, ARMS was used to detect EGFR and KRAS gene mutation, and the correlation with clinical pathology and prognosis was determined. Result In 134 patients, 53 had EGFR mutation, with a mutation rate of 39.55%, and there were 6 cases of KRAS gene mutation, the mutation rate was 4.48%.The mutation rate of EGFR gene in lung adenocarcinoma was related to age and smoking history（P〈0.05）. The incidence of KRAS gene mutation in patients with EGFR mutant lung adenocarcinoma was significantly lower than that those with wild-type EGFR（P〈0.05）. The PFS of patients with EGFR mutations was significantly longer than those with wild-type EGFR（P〈0.05）, besides, patients with wild-type KRAS had longer PFS than those with KRAS mutations（P〈0.05）. Con Conclusion KRAS gene in EGFR mutant lung adenocarcinoma patients is more likely to be wild type, and patients with EGFR gene mutation or wild-type KRAS gene have longer PFS.

关 键 词：肺腺癌 表皮生长因子受体 KRAS基因 基因突变 预后 

分 类 号：R734.2[医药卫生—肿瘤]